Acorda Therapeutics (NASDAQ:ACOR) provides 2019 highlights and 2020 guidance at the Annual JPM Conference in San Francisco.
2019 total and product revenue of ~$188M and $178M, respectively.
2019 AMPYRA sales of $162.6M.
2019 INBRIJA net revenue of $15.3M.
2020 total revenue expected in the range of $130M-$160M.
2020 product revenue to be $120M – $150M.
2020 INBRIJA revenue is expected to be $35M – $40M.
2020 AMPYRA revenue is expected to be $85M – $110M.
#JPM20
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.